proglumide has been researched along with Hepatocellular Carcinoma in 3 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition." | 5.91 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023) |
| "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition." | 1.91 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shivapurkar, N | 3 |
| Gay, MD | 3 |
| He, AR | 1 |
| Chen, W | 1 |
| Golnazar, S | 1 |
| Cao, H | 3 |
| Duka, T | 1 |
| Kallakury, B | 2 |
| Vasudevan, S | 1 |
| Smith, JP | 3 |
| Safronenka, A | 2 |
| Liu, FH | 1 |
| Malchiodi, ZX | 1 |
| Tucker, RD | 2 |
| Kroemer, A | 1 |
| Ciofoaia, V | 1 |
| Nadella, S | 1 |
| Huber, M | 1 |
| Kruger, AJ | 1 |
| Kroemer, AHK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH)[NCT04152473] | Phase 1 | 18 participants (Actual) | Interventional | 2019-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for proglumide and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholecystokinin; Fibrosis; Immune Checkpoint Inhibitors; Liver N | 2023 |
Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokines, CC; Cholecystokinin; Diet, High-Fa | 2021 |
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Choline Deficiency; Disease Models, Animal; Ep | 2020 |